A Phase I Clinical Study to Evaluate CS585 for Cardiovascular Diseases
Latest Information Update: 07 May 2021
At a glance
- Drugs CS 585 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- 07 May 2021 New trial record
- 28 Apr 2021 According to a Cereno Scientific media release, the company announced a collaboration agreement for the full preclinical development program of the new drug candidate CS585, which has been signed with the University of Michigan. The development agreement includes the successful transition of CS585 to a clinical Phase I program.